ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Waxman Hearing Turns Out Strong Support For Cancer Program Renewal

February 29, 1980

FDA Publishes Two Guidances for Lab-Developed Tests

October 3, 2014

First Panel Meeting On Centers Generates Possible Recommendations For Core Grant Guideline Changes

April 6, 1984

Funding opportunities listed.

October 29, 2004

DeVita Distressed Over “Misinformation” Circulation On Organ Systems Program

April 8, 1983

In Brief: Breast Cancer Stamp Unveiled; Payne Moves To MSK; Survivor To Bike Across U.S.

July 31, 1998